|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Amlodipine#Warnings]] |
| {{Amlodipine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| ===Hypotension===
| |
| | |
| Symptomatic [[hypotension ]]is possible, particularly in patients with severe [[aortic stenosis]]. Because of the gradual onset of action, acute hypotension is unlikely.
| |
| | |
| ===Increased Angina or Myocardial Infarction===
| |
| | |
| Worsening [[angina ]]and [[acute myocardial infarction]] can develop after starting or increasing the dose of NORVASC, particularly in patients with severe obstructive [[coronary artery disease]].
| |
| | |
| ===Beta-Blocker Withdrawal===
| |
| | |
| NORVASC is not a [[beta-blocker ]]and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of the dose of [[beta-blocker]].
| |
| | |
| ===Patients with Hepatic Failure===
| |
| | |
| Because NORVASC is extensively metabolized by the liver and the plasma elimination half-life (t 1/2) is 56 hours in patients with impaired hepatic function, titrate slowly when administering NORVASC to patients with severe [[hepatic impairment]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49#nlm42230-3 | publisher = | date = | accessdate = 6 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |